Blood glucose-lowering mechanism of Poria aqueous extract by UPLC-Q-TOF-MS/MS combined with network pharmacology and experimental verification.
10.19540/j.cnki.cjcmm.20250304.403
- Author:
Dan-Dan ZHANG
1
;
Wen-Biao WAN
2
;
Qing YAO
1
;
Fang LI
1
;
Zi-Yin YAO
1
;
Xiao-Chuan YE
2
Author Information
1. Hubei Key Laboratory of Diabetes and Angiopathy, School of Pharmacy, Hubei University of Science & Technology Xianning 437100, China.
2. Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chinese Medicine Wuhan 430065, China.
- Publication Type:Journal Article
- Keywords:
Poria aqueous extract;
UPLC-Q-TOF-MS/MS;
diabetes mellitus;
intestinal flora;
network pharmacology
- MeSH:
Animals;
Rats;
Network Pharmacology;
Tandem Mass Spectrometry;
Male;
Drugs, Chinese Herbal/pharmacology*;
Chromatography, High Pressure Liquid;
Blood Glucose/drug effects*;
Rats, Sprague-Dawley;
Hypoglycemic Agents/administration & dosage*;
Poria/chemistry*;
Diabetes Mellitus, Experimental/metabolism*;
NF-kappa B/genetics*;
Gastrointestinal Microbiome/drug effects*;
Humans
- From:
China Journal of Chinese Materia Medica
2025;50(14):3980-3989
- CountryChina
- Language:Chinese
-
Abstract:
Ultra performance liquid chromatography-quadrupole-time-of-flight-mass spectrometry/mass spectrometry(UPLC-Q-TOF-MS/MS), network pharmacology, and animal experiments were integrated o explore the blood glucose-lowering effects and mechanisms of Poria aqueous extract. Firstly, the active components of Poria aqueous extract were identified by UPLC-Q-TOF-MS/MS. Subsequently, network pharmacology was employed to predict the blood glucose-lowering components and mechanisms of Poria aqueous extract. Finally, a rat model of diabetes mellitus, 16S rDNA sequencing, and Western blot were employed to investigate the blood glucose-lowering effect and mechanism of Poria aqueous extract. A total of 39 triterpenoids were identified in the Poria aqueous extract, among them, 25-hydroxypachymic acid, 25α-hydroxytumulosic acid, 16α-hydroxytrametenolic acid, polyporenic acid C, and tumulosic acid may be the main active ingredients for treating diabetes. The Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis revealed that Poria might exert its therapeutic effects through multiple pathways such as NOD-like receptor signaling pathway, nuclear factor-kappa B(NF-κB) signaling pathway, and tumor necrosis factor(TNF) signaling pathway. The results of animal experiments demonstrated that Poria aqueous extract significantly reduced the levels of blood glucose and lipids and regulated the intestinal flora in diabetic rats. The main affected taxa included g＿Escherichia-Shigella, g＿Corynebacterium, g＿Prevotella＿9, g＿Prevotellaceae＿UCG-001, and g＿Bacteroidota＿unclassified. In addition, Poria aqueous extract lowered the levels of D-lactic acid and lipopolysaccharide, alleviated colonic mucosal damage, significantly down-regulated the protein levels of NOD-like receptor pyrin domain-containing protein 3(NLRP3), NF-κB, and TNF-α, and significantly up-regulated the protein levels of zonula occludens 1 and occludin in diabetic rates. Poria aqueous extract may play a role in treating diabetes mellitus by repairing the intestinal flora disturbance, protecting the intestinal barrier function, and inhibiting the NF-κB/NLRP3 signaling pathway. The results provide a scientific basis for clinical application and expansion of indications of Poria.
